Atorvastatin

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Atorvastatin

Examples of brand names: Sortis [DE]

ATC code: C10AA05

Main use (for orientation): Dyslipidaemia

Documented research summary

Within the documented search scope, no sufficiently attributable cannabinoid pair is established for Atorvastatin. The structured assessment distinguishes documented drug context from the absence of specific interaction evidence. Missing data do not establish safety.

Uncertainties and limitations

Do not add separately observed effects or extrapolate indiscriminately across all statins. Do not independently change prescribed medicines on the basis of this research dataset.

Structured assessment

Category: Drug context

Cannabinoid scope: No specifically substantiated pair involving a registered cannabinoid in the material assessed; no claim that all 28 cannabinoids were comprehensively reviewed simultaneously.

Evidence status: Drug properties supported by product information; insufficient evidence for a specific cannabinoid–drug pair effect.

Mechanism / drug context: CYP3A4, active metabolites and transporters such as OATP/BCRP/P-glycoprotein.

Type of supporting material: Product information and documented individual literature screening; no clinical pair trial approved for use as evidence.

Clinical interpretation: Cannabinoid-related statin exposure or frequency of muscle injury has not been measured.

Context: Single-ingredient atorvastatin preparation assessed; separate animal-study arms and synthetic agonists were not counted as a CBD combination.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [VD_LABEL_D0232]: Original product information: drug context, not evidence for a cannabinoid–drug pair

Statement supported: CYP3A4, active metabolites and transporters such as OATP/BCRP/P-glycoprotein.

Source: ATORVASTATIN CALCIUM TABLET, FILM COATED [PD-RX PHARMACEUTICALS, INC.] – DailyMed SPL [VD_LABEL_D0232]

Source role [VD_MED_42653071]: Documented research / scope-distinction context; no cannabinoid–drug pair evidence approved for use

Statement supported: Single-ingredient atorvastatin preparation assessed; separate animal-study arms and synthetic agonists were not counted as a CBD combination.

Source: Safety and Efficacy Assessment of Cannabis Plant Compared to Atorvastatin for Lipid Lowering in Diabetic and Obese Wistar Male Rats. [VD_MED_42653071]

Source role [VD_MED_40294080]: Documented research / scope-distinction context; no cannabinoid–drug pair evidence approved for use

Statement supported: Single-ingredient atorvastatin preparation assessed; separate animal-study arms and synthetic agonists were not counted as a CBD combination.

Source: Prospective DDI Risk Assessment of Vicasinabin with PBPK Modeling by Integrating In Vitro Data. [VD_MED_40294080]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: All individual review fields read. Original product information was rechecked only in the relevant pharmacokinetic/interaction excerpts; no complete recertification of all labels or worldwide full-text search. Literature access was based on the previously documented review; only the listed web sources were additionally read in this round. Do not add separately observed effects or extrapolate indiscriminately across all statins.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[VD_LABEL_D0232] ATORVASTATIN CALCIUM TABLET, FILM COATED [PD-RX PHARMACEUTICALS, INC.] – DailyMed SPL

Original source / bibliographic reference

Authors: Marketing authorisation holder / label provider according to the linked DailyMed product information

Year: 2026

Source type: Regulatory product information (US SPL)

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VD_MED_42653071] Safety and Efficacy Assessment of Cannabis Plant Compared to Atorvastatin for Lipid Lowering in Diabetic and Obese Wistar Male Rats.

Original source / bibliographic reference

Authors: Mărănducă MA, Clim A, Floria M, Tănase DM, Tamba B, Szilagyi A, Filipiuc LE, Gogu MR, Cozma CT, Șerban DN, Șerban IL.

Year: 2026

Source type: research-article; Journal Article

DOI: 10.3390/life16081383

PMID: 42653071

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

[VD_MED_40294080] Prospective DDI Risk Assessment of Vicasinabin with PBPK Modeling by Integrating In Vitro Data.

Original source / bibliographic reference

Authors: Umehara K, Parrott N, Günther A, Bogman K.

Year: 2025

Source type: Research Support, Non-U.S. Gov't; Journal Article

DOI: 10.1002/cpt.3686

PMID: 40294080

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility